Loading the section…

NPCE: financial statements from SEC — TradeAlmanac

NPCE

Neuropace, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	100M	80M
Cost of revenue	23M	21M
Gross profit	77M	59M
Research and development	28M	24M
Selling, general and administrative	19M	17M
Operating expenses	94M	81M
Operating income	−16M	−22M
Net income	−21M	−27M
Earnings per share	−0.66	−0.93
Earnings per share, diluted	−0.66	−0.93
Weighted average shares	33M	29M
Weighted average shares, diluted	33M	29M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	15M	22M	21M	23M	27M	13M	15M	13M
Short-term investments	39M	39M	39M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−11M	−18M
Depreciation and amortisation	238,000	207,000
Share-based compensation	11M	10M
Capital expenditure	332,000	306,000
Investing cash flow	−332,000	9M
Share buybacks	50M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator